Menarini bets on Georgiamune's GIM-621 with $1.1B deal. Menarini and Stemline license Georgiamune's preclinical immunotherapy GIM-621 in a deal worth up to $1.1 billion, plus royalties, for solid tumors. Menarini Group and its oncology subsidiary Stemline Therapeutics have secured exclusive worldwide rights to develop and commercialize GIM-621, an oral small-molecule immunotherapy in preclinical development for multiple solid tumors. Georgiamune will receive $45 million in upfront and near-term payments, with additional development, regulatory and commercial milestones potentially bringing the deal value to $1.1 billion, plus royalties. GIM-621 expands Menarini's solid tumor pipeline. GIM-621 is a preclinical-stage candidate emerging from Georgiamune's research into immune signaling pathways that regulate immune-cell activation, suppression and homeostasis. The company describes it as a first-in-class oral immunotherapy with potential applications across multiple solid tumors. The agreement gives Stemline exclusive worldwide rights to develop, manufacture and commercialize the candidate. The transaction expands Menarini's oncology pipeline with an early-stage immunotherapy program that could complement its existing solid tumor portfolio. However, GIM-621 remains at the preclinical stage. Its potential to produce meaningful antitumor activity in humans has not yet been established, and the companies have not disclosed specific tumor indications, preclinical efficacy results or the molecular target in the announcement. Deal structure links payments to development progress. Georgiamune will receive $45 million in upfront and near-term payments. It is also eligible for additional payments tied to preclinical, clinical development, regulatory and commercial milestones, bringing the potential transaction value to up to $1.1 billion. The agreement also includes royalties on future commercial sales. The headline deal value represents the maximum potential consideration rather than guaranteed revenue for Georgiamune. Most of the additional payments depend on GIM-621 meeting specified development and commercial milestones. For Menarini, the agreement provides access to a new immunotherapy candidate before clinical development, with Stemline taking responsibility for its development, manufacturing and commercialization worldwide. The financial structure also links a substantial portion of the potential expenditure to future progress. Immune signaling research underpins the program. Georgiamune focuses on therapies that reprogram immune signaling pathways in cancer and autoimmune diseases. Its research examines mechanisms that control immune-cell function, with the goal of translating these findings into new treatments. The company has positioned GIM-621 as one of several candidates arising from this research platform. According to founder and chief executive Samir N. Khleif, MD, Georgiamune also has three programs in clinical development across oncology and autoimmune diseases. The announcement does not identify GIM-621's precise molecular mechanism, the immune-cell populations it affects or the experimental evidence supporting its first-in-class designation. These details will be important for assessing how the candidate differs from existing immunotherapies and whether its oral administration offers a practical advantage. Menarini adds an early-stage oncology asset. Menarini chief executive Elcin Barker Ergun said GIM-621 complements the group's solid tumor portfolio and that its oncology development and commercial infrastructure could support the program's advancement. The partnership brings together Georgiamune's immunology research and Menarini's global oncology capabilities. Nevertheless, the candidate's preclinical status leaves several key questions unanswered, including its safety profile, therapeutic window, activity across tumor types and suitability for clinical testing. Neither company disclosed a planned first-in-human trial date, an initial clinical indication or a development timeline. What comes next for GIM-621? The next important milestones will be the disclosure of GIM-621's molecular target, preclinical efficacy and safety data, and plans for initiating clinical development. These findings will help establish whether the candidate can progress into human studies and support its proposed use across multiple solid tumors. For now, the agreement represents a significant licensing transaction around an early-stage immunotherapy program, rather than evidence of clinical benefit. Its long-term value will depend on whether preclinical findings translate into acceptable safety and meaningful antitumor activity in patients. Reference. Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent, Menarini group, 22 October 2026 About the Writer Creola Gonsalves (Linkedin) is an M.S. Biotechnology postgraduate with a strong interest in clinical research, evidence interpretation, and healthcare writing, with a focus on translating life-science knowledge into meaningful real-world insights. She is trained in Good Clinical Practice (GCP), clinical research principles, and critical interpretation of randomized clinical trials, with certifications from NIH and Stanford University. Her research background in biotechnological applications and microbial research strengthens her ability to understand scientific evidence and develop clear, accurate, and research-driven healthcare content.

Georgiamune and Menarini Group enter exclusive global license and collaboration agreement for GIM-621, a first-in-class oral immuno-oncology agent. * GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. * Georgiamune to receive $45 million in upfront and near-term payments, as part of a total deal value of up to $1.1 billion, plus royalties. FLORENCE, Italy and GAITHERSBURG Md., Oct. 22, 2026 (GLOBE NEWSWIRE) - The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, along with Georgiamune Inc., a clinical-stage biotechnology company discovering and developing first-in-class therapies that reprogram immune signaling pathways to treat cancer and autoimmune diseases, today announced an exclusive worldwide license and collaboration agreement for GIM-621. GIM-621 is a preclinical-stage first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. It is one of multiple therapeutic candidates generated from Georgiamune's research into novel mechanisms governing immune activation, suppression and homeostasis. Under the terms of the license and collaboration agreement, Stemline receives an exclusive, worldwide license to develop, manufacture and commercialize GIM-621. Georgiamune will receive $45 million in upfront and near-term payments. Georgiamune is also eligible for preclinical, development, regulatory and commercial milestone payments, for a total potential deal value of up to $1.1 billion, plus royalties. "At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology," said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. "GIM-621 is one of multiple programs to emerge from that work, alongside three programs already in clinical development across autoimmune disease and oncology. This agreement brings Menarini's global oncology development and commercial capabilities to GIM-621 while allowing Georgiamune to continue advancing a broad pipeline built on distinct immune mechanisms." "We are delighted to partner with Georgiamune, a company with deep expertise in immuno-oncology which has led to the discovery of GIM-621, a first-in-class oral immunotherapy with promise across multiple solid tumors," said Elcin Barker Ergun, CEO of the Menarini Group. "This program is a strong complement to our solid tumor portfolio, and our established oncology development and commercial capabilities position us well to accelerate its progress. We look forward to working closely with the Georgiamune team to unlock the full potential of this innovative approach to benefit patients with cancer." About Georgiamune Georgiamune is a clinical-stage biotechnology company discovering and developing first-in-class therapies designed to reprogram immune signaling pathways to treat cancer and autoimmune disease. The company's research focuses on novel mechanisms that govern T-cell activation, regulatory T-cell function and immune homeostasis. Georgiamune has three clinical-stage programs: GIM-407, an oral Treg activator in autoimmune disease; GIM-122, a dual-functioning antibody in oncology; and GIM-531, an oral Treg inhibitor in oncology. Georgiamune is also advancing a broader pipeline of preclinical candidates across oncology and autoimmune disease, including GIM-621. The company was founded by Dr. Samir N. Khleif based on discoveries from his laboratory into mechanisms that control immune responses. For more information, visit www.georgiamune.com. About The Menarini Group The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of $5.5 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini's products are available in 140 countries worldwide. For further information, please visit www.menarini.com. About Stemline Therapeutics Inc. Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on bringing transformational oncology treatments to patients. Stemline commercializes elacestrant, an oral endocrine therapy indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy, in the U.S., Europe, and other global regions. Stemline also commercializes tagraxofusp-erzs, a novel targeted therapy directed to CD123, for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States, Europe, and other global regions. In addition, Stemline commercializes selinexor, an XPO1 inhibitor for multiple myeloma, in Europe. The company is also conducting multiple label-expansion studies with elacestrant and tagraxofusp in breast and hematologic cancer indications, respectively, and has an extensive clinical pipeline of additional drug candidates in various stages of development for a host of solid and hematologic cancers.